Senescent Macrophages Fuel Liver Disease and Aging-Related Inflammation
Background
The global prevalence of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), formerly NAFLD, is rising, often progressing to more severe forms like MASH (Metabolic Dysfunction-Associated Steatohepatitis) and cirrhosis. A key driver of MASLD progression is inflammaging, a chronic low-grade inflammation associated with aging. While macrophages are known to play a role in liver inflammation, the specific contribution of senescent macrophage subsets to MASLD pathogenesis and inflammaging has remained poorly understood.
Study Design
Results
The study identified a distinct population of p21+TREM2+ senescent macrophages that significantly accumulated in the livers of MASLD mouse models and human patients. These cells showed a remarkable 3.5-fold increase in MASLD livers compared to healthy controls (p<0.001), correlating strongly with disease severity. Functionally, these senescent macrophages exhibited elevated expression of pro-inflammatory cytokines (e.g., IL-6, TNF-α) and pro-fibrotic genes, actively contributing to the overall inflammaging phenotype. Genetic or pharmacological depletion of these p21+TREM2+ senescent macrophages resulted in a 48% reduction in hepatic steatosis and a 35% decrease in liver fibrosis markers in MASLD models (p<0.001), demonstrating their causal role in disease progression.
Why It Matters
This research identifies p21+TREM2+ senescent macrophages as a critical and previously unrecognized driver of MASLD and associated inflammaging. The findings provide a novel understanding of how cellular senescence contributes to chronic liver disease, opening new avenues for therapeutic intervention. Targeting these specific senescent cells or their pathways could offer a promising strategy to prevent or reverse MASLD progression and mitigate age-related inflammation. Future steps include validating these findings in larger human cohorts and developing specific senolytic agents or immunomodulators for clinical trials.